SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Neurobiological Tech (NTII) -- Ignore unavailable to you. Want to Upgrade?


To: Cacaito who wrote (350)8/8/1998 11:12:00 AM
From: NeuroInvestment  Read Replies (2) | Respond to of 1494
 
It was Neurocrine Biosciences, not Neurogen, that announced the patents. It has, so far as I can see, zero impact upon NTI. NTI had already inlicensed the right to use CRF in inflammatory conditions from the Salk Institute. NBIX's patents mean that other companies would not be able to clone those receptors in the service of developing molecules that would 'key' into them, for whatever purpose. Xerecept would not be affected by this. NeuroInvestment (neuroinv@neuroinv.com)